RPTH/ LinkedIn
Aug 26, 2025, 09:54
TSUBASA Study: Emicizumab Improves Daily Life and Motivation in Hemophilia A Patients
RPTH Journal shared an insightful post on LinkedIn:
“Patient-reported improvements in physical activity and work motivation, and maintained quality of life, are observed when people with hemophilia A are treated with emicizumab in the TSUBASA study.”
Read the full article here:
Article: TSUBASA study: evaluation of the quality and content of daily life of people with hemophilia A without factor VIII inhibitors on prophylactic treatment with emicizumab
Authors: Teruhisa Fujii, Keiji Nogami, Akihiro Sawada, Azusa Nagao, Chiai Nagae, Masanori Nojima, Nobuaki Suzuki, Mika Kawano, Tomomi Shimura, Yoshimasa Sugao, Kagehiro Amano
Stay up-to-date with the latest developments in hematology through Hemostasis Today.
-
Apr 12, 2026, 17:34Caitlin Raymond: Granulocyte Transfusions for the Overworked Fellow
-
Apr 12, 2026, 17:33Augustina Isioma Ikusemoro: ABO Typing Is Not the Same in Infants and Adults
-
Apr 12, 2026, 17:32Bastu Odoka: Same Blood Group Does Not Guarantee Compatibility
-
Apr 12, 2026, 17:31Jack Hadfield: SARS-CoV-2–Associated Lasting Mitochondrial Injury in Cardiomyocytes
-
Apr 12, 2026, 17:30Flora Peyvandi: ABB Milan Presentations During the ISTH 2026
-
Apr 12, 2026, 17:01Hafiz Saad Ullah: Introducing to Fully Automatic Peripheral Blood Smear Stainer
-
Apr 12, 2026, 16:53Najmul Hasan Forhad: A Simple Framework for Mastering Anticoagulant Therapy
-
Apr 12, 2026, 16:36Piotr Czempik: Patient Blood Management Means Safer Care, Better Quality, and Responsible Resource Use
-
Apr 12, 2026, 16:31Eishi Asano: Available Evidence and Unmet Needs in EEG Use During Stroke Management